Evidence map›Paper›PMID 42054448›Full record

ArticleScience advances2026

In vivo membrane engineering traps Gd-based MRI contrast agents for detecting microhepatocellular carcinoma.

Chunping Mao, Jie Yi, Fuan Deng, Wanning Zhu, Jiaru Zhao, Hualing Li, Luoxing Xia, Jianing Ji, Yuxiang Xiong, Jiayao Cai and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Chunping MaoDepartment of Radiology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.ORCID 0000-0002-5957-9550
Jie YiDepartment of Gastroenterology, Jingmen Central Hospital, Jingmen 448000, China.ORCID 0009-0001-4945-9176
Fuan DengGuangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen 518055, China.ORCID 0009-0008-4874-5040
Wanning ZhuDepartment of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China.ORCID 0009-0003-3037-5161
Jiaru ZhaoDepartment of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China.
Hualing LiGuangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen 518055, China.
Luoxing XiaDepartment of Radiology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.ORCID 0009-0006-8424-8805
Jianing JiGuangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen 518055, China.
Yuxiang XiongGuangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen 518055, China.
Jiayao CaiDepartment of Radiology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
Lingdong JiangGuangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen 518055, China.
Jun ShenDepartment of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China.ORCID 0000-0001-7746-5285
Guobin HongDepartment of Radiology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.ORCID 0000-0002-2690-7802
Lu ZhangDepartment of Radiology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.ORCID 0000-0002-7492-6047

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate detection of microhepatocellular carcinoma (HCC) remains a major clinical challenge owing to the limited specificity and sensitivity of current imaging modalities. Herein, we present a dual-injection magnetic resonance imaging (MRI) peptidic probe based on in vivo membrane engineering, achieving in situ signal amplification and molecularly precise imaging. The first injection of programmable nanoparticles coassembled from two peptide monomers, incorporating a GPC3-targeting ligand, a β sheet-forming motif, a dibenzocyclooctyne (DBCO) handle, and porphyrin IX (PpIX) for fluorescence tracking. Following systemic administration, the nanoparticles high-specifically bind to GPC3-overexpressing tumor membranes and transform into surface-anchored nanofibrils, exposing confined DBCO groups. A second injection of azide-modified Gd-DOTA enables rapid copper-free click conjugation on the nanofibrillar scaffold, yielding a nearly fourfold increase in longitudinal relaxivity. MRI demonstrated strong

Indexed as

Carcinoma, HepatocellularContrast MediaGadoliniumLiver NeoplasmsMagnetic Resonance ImagingAnimalsCell Line, TumorHumansMiceNanoparticlesContrast MediaGadolinium

Identifiers

PMID42054448
PMCPMC13127589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.